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Stem cells are dividing cells that exhibit potency (ability 
to subdivide into multiple different cells types) and self-
renewal (ability to undergo multiple cell cycles without 
differentiation). The degree of potency can be considered 
as totipotent (can divide into any cell type), pluripotent 
(descendants of totipotent cells and can divide into cells 
from endoderm, mesoderm, or ectoderm), or multipotent 
(division is limited to cell types from a single family). Stem 
cells are found in embryos, cord blood, and (in adults) bone 
marrow and stromal tissue. In 2006, Yamanaka demon-
strated that adult stem cells may be induced to form pluri-
potent stem cells, i.e., could increase their potency. This 
and other advances in stem cell research have generated 
increasing interest across a broad range of medical speci-
alities because of the potential for therapeutic effects such 
as replacement of damaged cells, repair of damaged tissue 
by merging with endogenous cells, paracrine functions, and 
immunomodulatory effects.
The central nervous system (CNS) undergoes little endog-
enous neural cell division beyond selected regions such as 
the hippocampus and striatum. This limits the capacity of 
the brain and spinal cord to undergo repair and therefore 
results in more severe consequences from tissue damage. In 
addition, the lack of endogenous repair mechanisms almost 
certainly contributes to the widespread failure of many 
potential therapeutic agents hitherto trialed in degenerative 
CNS diseases, and the consequent paucity of effective dis-
ease modifying drugs currently available. In treating disease, 
therapeutic approaches can employ a wide range of targets, 
but, broadly, these fall into either a cessation of a pathologi-
cal process, an enhancement of a protective mechanism, or 
regeneration of damaged tissue. The application of stem cell 
therapeutics in CNS disease has the potential to address all 
three pathways and generated understandable excitement in 
the neuroscience community. However, as with all research 
endeavours, enthusiasm should be tempered with robust bio-
logical rationale, rigorous ethical and methodological over-
sight, and clear and consistent trial methodology to show the 
evidence of benefit.
This month’s journal club covers three papers dealing 
with stem cells as therapeutic interventions in CNS dis-
ease. First, a randomised-controlled trial of intravenous 
mesenchymal stem cells as an immunomodulatory therapy 
to reduce inflammatory mediated neural damage in stroke; 
second, a dopaminergic cell replacement in an animal model 
of Parkinson’s disease. Finally in a break from our usual con-
vention for journal club; an important overview and guid-
ance for research using stem cells for immunomodulation 
and brain repair in multiple sclerosis.
Safety and efficacy of multipotent adult 
progenitor cells in acute ischaemic stroke 
(MASTERS): a randomised, double‑blind, 
placebo‑controlled, phase 2 trial
To date, there are no effective treatments for neuroprotec-
tion or brain repair in stroke. The previous studies of stem 
cell treatment in stroke have been small, single-centre stud-
ies. This is the first large multi-centre study of intravenous 
multipotent stem cells in the treatment of cerebral damage 
secondary to stroke.
MASTERS was a phase II randomised-controlled trial, 
with primary outcomes for safety and efficacy. Patients with 
a confirmed anterior circulation infarction on MRI treated 
with thrombolysis, aged 18–79, and with an NIHSS score 
of 8–20 were recruited. Cells were given intravenously 
between 24 and 48 h after the index event. The initial 8 
patients received 400 million cells/kg of body weight; a 
planned dose escalation increased this to 1200 million cells/
kg. Participants were randomised by computer, the interven-
tion group received cells plus vehicle, and the control group 
received vehicle alone. Participants were assessed at 7, 30, 
90, and 365 days using the modified Rankin Scale (mRS), 
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NIHSS, and Barthel index scales; exploratory outcomes 
were MR volume change and levels of cytokines and regu-
latory T cells. Primary safety outcomes were dose-limiting 
toxic events at 7 days after infusion, allergic/adverse events 
secondary to cells, or worsening NIHSS of 4 points. Second-
ary safety outcomes were diagnosis of infection, mortality, 
or changing vital signs. The primary efficacy outcome was 
a compound outcome of mRS < 2, NIHSS improvement 
of > 75%, and a Barthel score of > 94. Secondary outcomes 
were change in mRS, improvement in NIHSS to < 1 or by 
more than 10 points, and ‘excellent outcome’ (Barthel > 94, 
mRS 0–1, NIHSS 0–1). Data were analysed on an intention 
to treat basis.
129 patients were randomised, 8 patients received the 
lower dose of cells, 65 patients received the cells, and 61, 
placebo. The groups were well matched for age and median 
NIHSS score. There were no differences on any of the safety 
outcomes. There were also no differences on any of the 
primary efficacy outcome measures. An improvement on 
only one of the secondary outcomes was seen: “excellent 
outcome”.
Comments and conclusions. There were no differences 
between the groups on any of the safety outcomes. Although 
this trial was not powered to look for efficacy outcomes, one 
of the secondary outcomes did show an improvement in the 
intervention group; however, the significance level would 
not have been met after correction for the family-wise error 
rate. Furthermore, the biological rationale for intravenous 
mesenchymal stem cells in stroke is not compelling based 
on the cited animal literature: the authors hypothesise that 
stem cells may act as immunomodulators, rather than replace 
damaged neurons and glia.
Hess DC et al. (2017) Lancet Neurology 16:360–368.
Human iPS cell‑derived dopaminergic 
neurons function in a primate Parkinson’s 
disease model
Previous work has demonstrated that it is possible to suc-
cessfully graft primates with nigro-striatal lesions, with neu-
rons derived from embryonic stem cells and human fetal 
stem cells. This is the first study demonstrating that it is 
possible to graft these primates with induced Pluripotent 
Stem (iPS) cells derived from humans.
Cells were derived from 3 patients with Parkinson’s dis-
ease (screened for common genetic Parkinson’s mutations) 
and 5 healthy controls. IPS cells were induced using stand-
ard methods. Cells were stained for floor-plate markers and 
patch-clamp stimulation to confirm successful differentia-
tion and function as midbrain neurons. 11 MPTP lesioned 
cynomolgus monkeys were used in the experiment. They 
were split into 3 groups and had putaminal grafts: either iPS 
cells from PD patients, iPS cells from controls, or vehicle 
only (i.e., no cells). Graft growth, tumorogenesis, and func-
tion were measured using MRI and PET scans. The mon-
key’s movement disorder was assessed by blinded observers 
using a standardised assessment, and also by pixel change on 
standardised videos. The animals were then euthanised and 
tumorigenic markers were assessed histologically. ANOVAs 
were used for group comparison, and linear regression for 
change over time.
Scores on both the formalised examination and video-
analysis were significantly higher in the grafted groups than 
the ungrafted groups. MR analysis showed an increase in 
graft size (mean peak volume 39.4 mm3) until 6–9 months 
and a plateau of volume thereafter. PET analysis showed no 
tracer uptake of FLT (a marker of tumorogenesis); survival 
and function of the dopaminergic graft were confirmed in 
all grafted animals. There were no differences on any of 
the measures between grafts from PD patients and normal 
controls. No monkey had evidence of inflammatory infiltrate 
or rosette-forming cells to suggest tumour formation or host-
mediated attack on the graft.
Comments and conclusions. We consider this to be a 
study of considerable importance; it is the first demon-
stration that human-derived iPS stem cells can form dopa-
minergic neurons, be safely grafted, and restore function 
in animals with an objective movement disorder. The fact 
that there was no difference in cell lines derived from PD 
patients and human controls, suggests that PD patients could 
form their own transplants obviating the need for allograft 
and immunosuppression. The sample size is small, and 
the method for choosing which animals to graft is unclear. 
Nevertheless, this study offers encouragement in using this 
methodology for the potential future treatment of Parkin-
son’s disease.
Kikuchi T et al. (2017) Nature 548:592–609.
Cell‑based therapeutic strategies 
for multiple sclerosis
A wide variety of approaches and cell lines have been 
employed to interrogate the potential for stem cell therapies 
in multiple sclerosis (MS). Current disease modifying thera-
pies (DMTs) carry significant side effects, and there are no 
current effective treatments for progressive disease or cell 
repair. This review article summarises the current evidence 
base in this field and offers guidelines for future research 
and clinical practice.
Immunoablation and Autologous Haematopoietic Stem 
Cell Transplant (IAHSCT): The rationale for this approach 
is to modify the immune system by ablation and replace-
ment of the host-sensitised immune system. Evidence has 
accrued that this approach switches the immune response 
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to a Th1-mediated pathway, and autoreactive T cells are 
reduced. Initially this methodology was employed in pro-
gressive patients with little success; however, more recently, 
it has been used for highly aggressive relapsing–remitting 
disease with more promising results. Researchers have used 
an ablative agent (cyclophosphamide and alemtuzumab) 
followed by GCSF to re populate the immune system. 
Early approaches used busulphan and whole-body irradia-
tion which resulted in unacceptable toxicity. There are few 
head-to-head trials with conventional DMTs, but retrospec-
tive analysis of the published data suggests that NEDA (no 
evidence of disease activity) is achieved in up to 80%, com-
pared with 46% on conventional DMTs. Mortality is less 
than 5%, with serious adverse events in 9%. The authors 
recommend (1) selecting relapsing–remitting patients with 
highly active disease, who have failed on DMTs, (2) head-
to-head trials with conventional DMTs; and (3) any patients 
treated outside a clinical trial should be entered on a register.
Mesenchymal stem cells. Mesenchymal stem cells 
(MSCs) are present in almost all body tissues; they are 
involved in tissue repair and also have a paracrine function; 
which may mediate their effects in the CNS. There are a 
number of candidate mechanisms for their effects: re-mye-
lination, angiogenesis, neuroprotection, and reduced gliosis. 
However, there remain many uncertainties: the optimal dose 
of cells, whether the purification of the cell line is neces-
sary, and, finally, the need for pre-differentiation into neural 
progenitor cells. The lack of agreed end-points or outcomes 
for clinical trials is a major sticking point for future research, 
although, as most studies are at phase II, safety outcomes 
(such as tumour growth) are paramount. Most MSCs are 
delivered intravenously, and there is some evidence to sug-
gest they do reach the CNS, although some workers have 
delivered them directly into the CSF. There have been a 
few adverse events—albeit including 1 CNS malignancy. 
Two randomised-controlled trials have been negative. The 
authors highlight the need for standardisation of cell dose, 
number of infusions, and clarification of the need for purifi-
cation of the cell lines prior to transplant.
Oligodendrocyte progenitor cells (OPCs) and induced 
pluripotent cells (iPCs): Animal work has shown widespread 
re-myelination in a mouse model of MS treated with OPCs, 
the most myelinogenic cell lines can be selected by testing 
for PDGF alpha and CD140a. These cells must be injected 
into the CNS to act, but, by what mechanism, they localise 
to tissue damage (or if they do) remains unclear. Fetal cells 
are the main source of OPC, which necessitates immunosup-
pression. IPSCs obviate the need for immunosuppression but 
may have higher neoplastic potential than OPCs. A phase 1 
trial is underway.
Ethical issues and future directions. The authors rec-
ommend that all patients are informed of the experimental 
nature of these treatments, and research should adhere to 
relevant national and international guidelines. They further 
recommend an international registry for patients undergoing 
this treatment.
Comments and conclusions. IAHSCT has the most 
evidence to support its use in MS; however, it is unclear 
whether observed efficacy occurs as a consequence of 
aggressive immunosuppression, or alteration of the immune 
response. Evidence to support the use of MSCs in MS is 
sparser; and there is a lack of agreement in the literature 
about delivery method, dose, cell lines, and even mecha-
nism of action. OPCs and iPSCs have only shown promise 
in animal models to date.
Scolding J et al. (2017) Brain 140:2776–2796.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
